Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 2/20 | 0.44 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30140579 | 1.00 | MEN1 (0.47) | MEN1CYP1A2KMT2ACTSBCTSS | |
| SCHEMBL24754706 | 1.00 | MEN1 (0.47) | MEN1CYP1A2KMT2ACTSBCTSS | |
| SCHEMBL24962677 | 1.00 | MEN1 (0.47) | MEN1CYP1A2KMT2ACTSBCTSS | |
| SCHEMBL24963635 | 1.00 | MEN1 (0.47) | MEN1CYP1A2KMT2ACTSBCTSS | |
| SCHEMBL30140621 | 0.94 | CTSB (0.41) | CTSBCTSSCTSL | |
| SCHEMBL24963606 | 0.94 | CTSB (0.41) | CTSBCTSSCTSL | |
| SCHEMBL30140728 | 0.91 | CTSL (0.41) | CTSBCTSL | |
| SCHEMBL24963938 | 0.91 | CTSL (0.41) | CTSBCTSL | |
| SCHEMBL24754707 | 0.90 | MEN1 (0.48) | MEN1CYP1A2KMT2ACTSBCTSS | |
| SCHEMBL24755518 | 0.89 | CTSB (0.43) | CTSBCTSSCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230033285-A1 | Protease Inhibitors for Treatment of Coronavirus Infections | THE SCRIPPS RESEARCH INSTITUTE | 2023-02-02 | — | — | US | claimed |
| WO-2022266363-A1 | PROTEASE INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-12-22 | — | — | WO | claimed |
| US-20230033285-A1 | Protease Inhibitors for Treatment of Coronavirus Infections | THE SCRIPPS RESEARCH INSTITUTE | 2023-02-02 | — | — | US | disclosed |
| WO-2022266363-A1 | PROTEASE INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230033285-A1 | Protease Inhibitors for Treatment of Coronavirus Infections | ACE, ACE2, TMPRSS2 | MEN1 3185/4885CYP1A2 318/4885KMT2A 2364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.